Navigation Links
Oncothyreon reports second quarter 2009 financial results
Date:8/12/2009

SEATTLE, Aug. 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008. Oncothyreon recorded a non-cash charge of $2.5 million in the three months ended June 30, 2009 for the change in the fair value of warrants issued in connection with its May 2009 securities offering. The increase in net loss for the three-month period was primarily the result of this non-cash charge and a decrease in revenue described below, partially offset by decreased operating expenses.

Oncothyreon reported a net loss of $8.8 million, or $0.43 per basic and diluted share, for the six months ended June 30, 2009, compared with a net loss of $10.1 million, or $0.51 per basic and diluted share, for the comparable period in 2008. The decrease in net loss for the six-month period was primarily the result of the transfer of manufacturing activities for Stimuvax(R) to Merck KGaA in December 2008, which resulted in a decrease of combined research and development and manufacturing expenses partially offset by a decrease in both contract manufacturing and licensing revenue from collaborative agreements and the non-cash charge discussed above.

Total revenue was $31,000 and $35,000, respectively, for the three and six months ended June 30, 2009, compared to $1.2 million and $3.2 million for the same periods in 2008. The decrease in revenue was primarily the result of the transfer of manufacturing of Stimuvax to Merck KGaA in December 2008.

Total expenses for the three and six months ended June 30, 2009 were $6.4 million and $8.8 million respectively, compared with $6.1 million and $13.2 million for the com
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... San Francisco, CA (PRWEB) July 10, 2014 ... a family closer together. The Archer Family purchased ... information contained within DNA, but ended up with a ... surprising discoveries contained within the family members’ DNA genuinely ... family had decided to search deeper into genetic history ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007,Thomas ... at 1:30 p.m. Eastern Daylight Time. The conference ...
... PXS, Nasdaq: PXSL) today announced that its Phase ... people with bronchiectasis has met its two,primary efficacy ... Data from the 362 subject study demonstrated a ... weeks of treatment with Bronchitol,as assessed by the ...
... SOMERSET, N.J., Aug. 28 DOV Pharmaceutical,Inc. ("DOV" or ... today that its common stock is now being quoted ... common stock is also still,being quoted on the Pink ... common stock are now being quoted,both on the OTC ...
Cached Biology Technology:ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board 2
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... Social animals often develop relationships with other group members ... In wild chacma baboons the strategy for grooming activities ... are just published in the scientific journal Biology ... of baboons is not practiced without ulterior motives. To ... for the individual, while grooming another individual can provide ...
(Date:7/11/2014)... of mesenchymal stem cells can stimulate neurogenesis in the ... disease (AD) and improve tissue and function injury under ... on the therapeutic effect of adipose-derived stem cells (ADSCs) ... on oxidative injury and neurogenesis in the brain of ... of Life Sciences, Tsinghua University, China transplanted ADSCs into ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... BGI, the world,s largest genomic organization, today announced its ... of RNA-Seq in predicting patient outcomes as part of ... U.S. Food and Drug Administration (FDA). The SEQC, also ... MicroArray Quality Control (MAQC), aimed at assessing the technical ...
... upper and lower abdomen is a reliable, minimally invasive way ... indicator of too much male hormone, researchers report. "We ... women that was as non-intrusive and accurate as possible," said ... Sciences University. "We believe this approach is approximately ...
... controlled by the brain from blood pressure to appetite to ... , a team of scientists led by Dr. Gil Levkowitz of ... brain area in which biochemical commands are passed from the brain ... the process, they discovered a surprising new role for the ,hormone ...
Cached Biology News:BGI to play a pivotal role in demonstrating the superior performance of RNA-Seq 2Women's chin, abdomen are good indicators of excessive hair growth 2Women's chin, abdomen are good indicators of excessive hair growth 3A hormone ensures its future 2
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
... Resistant (X/R) Red System consists of ... Activator and X/R Red Buffer. The ... phosphatase to produce red staining that ... Contains:, , Buffer, 100 mL , ...
Human Cell Line Slides...
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: